Skip to content
Dalfampridine
Ampyra (dalfampridine) is a small molecule pharmaceutical. Dalfampridine was first approved as Ampyra on 2010-01-22. It is used to treat multiple sclerosis and neurologic gait disorders in the USA. It is known to target potassium voltage-gated channel subfamily B member 2, potassium voltage-gated channel subfamily D member 1, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily A member 10, and inward rectifier potassium channel 13.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ampyra (generic drugs available since 2017-01-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dalfampridine
Tradename
Company
Number
Date
Products
AMPYRAAcorda TherapeuticsN-022250 RX2010-01-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ampyraNew Drug Application2021-02-24
dalfampridineANDA2023-03-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple sclerosisEFO_0003885D009103G35
neurologic gait disordersHP_0003376D020233R26.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX07: Fampridine
HCPCS
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G3518117631
Chronic progressive multiple sclerosisD020528——11—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spinal cord injuriesD013119EFO_1001919113——5
Optic neuritisD009902EFO_0007405H46111——2
Muscle spasticityD009128HP_0001257——2——2
Prostatic neoplasmsD011471C61—11——1
Relapsing-remitting multiple sclerosisD020529EFO_0003929——1——1
Spinal muscular atrophyD009134EFO_0008525G12.1—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Short-term memoryD008570EFO_0004335—2——13
FatigueD005221HP_0012378R53.83—2———2
Prostatic diseasesD011469N42.9—1———1
Migraine disordersD008881EFO_0003821G43—1———1
Vestibular diseasesD015837EFO_0009691H81—1———1
Obstructive sleep apneaD020181EFO_0003918G47.33—1———1
Ocular motility disordersD015835EFO_1001990H50.54—1———1
Neuromyelitis opticaD009471EFO_0004256G36.0—1———1
Transverse myelitisD009188G37.3—1———1
MyelitisD009187G04.91—1———1
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Traumatic brain injuriesD000070642S061————1
Alzheimer diseaseD000544EFO_0000249F031————1
Demyelinating diseasesD0037111————1
Motor neuron diseaseD016472EFO_0003782G12.21————1
Cerebral palsyD002547G801————1
Renal insufficiencyD051437HP_0000083N191————1
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spinocerebellar ataxiasD020754————11
Machado-joseph diseaseD017827EFO_0004135————11
PregnancyD011247EFO_0002950Z33.1————11
Covid-19D000086382U07.1————11
Hereditary spastic paraplegiaD015419EFO_0000529G11.4————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDALFAMPRIDINE
INNfampridine
Description
4-aminopyridine is an aromatic amine that is pyridine bearing a single amino substituent at position 4. An orphan drug in the US, it is used to improve walking in adults with multiple sclerosis. It has a role as an avicide, a potassium channel blocker and an orphan drug. It is an aromatic amine and an aminopyridine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccncc1
Identifiers
PDB—
CAS-ID504-24-5
RxCUI897018
ChEMBL IDCHEMBL284348
ChEBI ID34385
PubChem CID1727
DrugBankDB06637
UNII IDBH3B64OKL9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNB2
KCNB2
KCND1
KCND1
KCNA5
KCNA5
KCNA10
KCNA10
KCNJ13
KCNJ13
Organism
Homo sapiens
Gene name
KCNB2
Gene synonyms
NCBI Gene ID
9312
Protein name
potassium voltage-gated channel subfamily B member 2
Protein synonyms
delayed rectifier potassium channel protein, potassium channel Kv2.2, potassium channel, voltage gated Shab related subfamily B, member 2, potassium voltage-gated channel, Shab-related subfamily, member 2, Voltage-gated potassium channel subunit Kv2.2
Uniprot ID
Q9BXD3
Mouse ortholog
Kcnb2 (98741)
potassium voltage-gated channel subfamily B member 2 (E9Q5T7)
Variants
Clinical Variant
No data
Financial
Ampyra - Acorda Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Ampyra - Alkermes
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Ampyra - Elan Corporation
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Ampyra - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 809 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,311 adverse events reported
View more details